Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 18, Issue 5, 2008, Pages 442-446

  Inokuma, Shigeko ^a,b   Sato, Takeo ^a,c   Sagawa, Akira ^a,d   Matsuda, Takemasa ^a,e   Takemura, Tamiko ^a,c   Ohtsuka, Takeshi ^a,f   Saeki, Yukihiko ^a,g   Takeuchi, Tsutomu ^a,h   Sawada, Tetsuji ^a,i  

^a Study Committee for Leflunomide Induced Lung Injury   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d Sagawa Akira Rheumatology Clinic   (Japan)

^e Kagoshima Red Cross Hospital   (Japan)

^f Munakata Medical Association Hospital   (Japan)

^g MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

Leflunomide; Lung injury; Proposals for leflunomide use; Rheumatoid arthritis

Indexed keywords

ACTIVATED CARBON; C REACTIVE PROTEIN; COLESTYRAMINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; SERUM ALBUMIN; STEROID; TERIFLUNOMIDE;

ABNORMAL LABORATORY RESULT; ALBUMIN BLOOD LEVEL; ALOPECIA; BACTERIAL INFECTION; BODY WEIGHT; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG URINE LEVEL; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; HEMOPHAGOCYTIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOXEMIA; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LOW BODY WEIGHT; LUNG ABSCESS; LUNG INFECTION; LUNG INJURY; LUNG MYCOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MYCOBACTERIOSIS; NAUSEA; PNEUMOCYSTIS PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SMOKING; STEROID THERAPY; TRACHEA INJURY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY SEDIMENTATION ABNORMALITY;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; ISOXAZOLES; JAPAN; LUNG INJURY; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 53549128108     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0088-2     Document Type: Review

References (14)

1. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet. 2004;363:461.
2. Ichikawa Y, Kamatani N, Goto M, Kondo H, Saito T, Suzuki Y, et al. Phase II dose ranging study of leflunomide in Japan. J New Rem & Clin. 2003;52:891-931.
3. Appended document of Arava® (in Japanese). Sanofi-Aventis Japan; 2006 revised.
4. Momo H, Suzuki H, Mitsuhashi H, Urata M, Nitta Y, Yasuda K. Evaluation of pharmacokinetics and safety of leflunomide (HWA486) in healthy adult men (author's translation). J New Rem & Clin. 2003;52:876-90.
5. Yasuda K, Momo H, Suzuki H, Urata M, Muraki S, Mitsuhashi H. Study of removal therapy of active metabolite (A771726) of leflunomide (HWA486) by colestyramine (author's translation). J New Rem & Clin. 2003;52:85-94.
6. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542-50.
7. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353:259-66.
8. Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group. J Rheumatol. 1998;53 (Suppl):27.
9. Prakash A, Jarvis B. Leflunomide - a review of its use in active rheumatoid arthritis. Drugs. 1999;58:1137-64.
10. Sawada T, Inokuma S, Sato T, Sagawa A, Matsuda T, Takemura T, et al. Leflunomide-induced lung diseases: Overview of its occurrence, and identification of risk factors. Mod Rheumatol. 2007;17(Suppl):99.
11. Sato T, Inokuma S, Sagawa A, Matsuda T, Ohtsuka T, Saeki Y, et al. Analysis of rheumatoid arthritis patients of died of and recovered from leflunomide-induced interstitial pneumonia. Mod Rheumatol. 2007;17(Suppl):100.
12. Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med. 2006;45:689-91.
13. Study Group of the Ministry of Health, Labour and Welfare. Therapeutic manual of rheumatoid arthritis (revised). Diagnostic manual and evidence-based treatment guidelines. Jpn Rheum Found; 2004.
14. Inokuma S, Kono H, Kohno Y, Hiramatsu K, Ito K, Shiratori K, et al. Methotrexate-induced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease. Ann Rheum Dis. 2006;65:1113-4.